GlassScriptPhysician profile
Jaime Mb Grubert
NPI 1326364555
$1,996.97
in general payments reported to CMS, 2019-2025
24 companies · $435 in 2025
The $435 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $121 · 2021: $264 · 2022: $265 · 2023: $303 · 2024: $430 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $236.39 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $235.94 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Ironshore Pharmaceuticals INC. | $180.86 | 2019-2024 | Jornay Pm |
| Corium, LLC | $177.20 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $170.99 | 2019-2022 | |
| Biomerieux INC | $155.59 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Neos Therapeutics, LP | $137.05 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Cranial Technologies, INC | $131.53 | 2019-2024 | Doc Band |
| Tris Pharma INC | $121.28 | 2020-2022 | |
| Seqirus USA INC | $82.49 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Novo Nordisk INC | $54.19 | 2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $40.68 | 2024-2025 | |
| Neurelis, INC. | $36.68 | 2021-2023 | Valtoco |
| Sanofi Pasteur INC. | $32.03 | 2023 | |
| Glaxosmithkline, LLC. | $31.55 | 2024-2025 | Bexsero |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $28.51 | 2024-2025 | Relexxii |
| Genentech USA, INC. | $28.17 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $24.08 | 2023 | Voxzogo 1.2mg |
| Verrica Pharmaceuticals INC. | $19.36 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $18.08 | 2024 | Flumist Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $15.95 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.71 | 2025 | Qelbree |
| Adlon Therapeutics L.P. | $13.00 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Grubert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.